Literature DB >> 761404

Determination of quinidine and metabolites in urine by reverse-phase high-pressure liquid chromatography.

M R Bonora, T W Guentert, R A Upton, S Riegelman.   

Abstract

A new reverse-phase high-pressure liquid chromatography assay allowing simultaneous but separate quantitation of urinary levels of quinidine and its major metabolites, 2'-quinidinone, 3-OH-quinidine and a newly detected N-oxide, is described. The compounds were separated on a alkyl phenyl column using 0.05 M phosphate buffer pH 4.5/acetonitrile/tetrahydrofuran (80 : 15 : 5, v/v) as mobile phase and were detected by UV at lambda = 230 nm. The assay procedure includes extraction of the compounds from urine samples into a mixture of dichloromethane/isopropanol (4 : 1, v/v), evaporation of the organic extracts to dryness and reconstitution of the residue in acetonitrile. The new assay was compared to a modification of the Cramer and Isaksson fluorescence assay which has recently been recommended for analysis of quinidine in urine. The consistently higher quinidine levels observed in the fluorescence assay could be accounted for by the quinidine levels and metabolite carry-over as determined by HPLC.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 761404     DOI: 10.1016/0009-8981(79)90484-4

Source DB:  PubMed          Journal:  Clin Chim Acta        ISSN: 0009-8981            Impact factor:   3.786


  5 in total

1.  Comparison of two long-acting forms of quinidine.

Authors:  A Leizorovicz; C Piolat; J P Boissel; B Sanchini; S Ferry
Journal:  Br J Clin Pharmacol       Date:  1984-06       Impact factor: 4.335

2.  Quinidine determination in serum: enzyme immunoassay (EIA) V HPLC.

Authors:  H R Ha; G Kewitz; M Wenk; F Follath
Journal:  Br J Clin Pharmacol       Date:  1981-03       Impact factor: 4.335

3.  Divergence in pharmacokinetic parameters of quinidine obtained by specific and nonspecific assay methods.

Authors:  T W Guentert; R A Upton; N H Holford; S Riegelman
Journal:  J Pharmacokinet Biopharm       Date:  1979-06

4.  Urinary excretion kinetics of intact quinidine and 3-OH-quinidine after oral administration of a single oral dose of quinidine gluconate in the fasting and non-fasting state.

Authors:  J M St-Onge; G Sirois; M A Gagnon
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1983 Oct-Dec       Impact factor: 2.441

Review 5.  Clinical pharmacokinetics of quinidine.

Authors:  H R Ochs; D J Greenblatt; E Woo
Journal:  Clin Pharmacokinet       Date:  1980 Mar-Apr       Impact factor: 6.447

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.